Gemcitabine + Oxaliplatin + Bevacizumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Trial Timeline
Sep 1, 2006 → Oct 1, 2011
NCT ID
NCT00418093About Gemcitabine + Oxaliplatin + Bevacizumab
Gemcitabine + Oxaliplatin + Bevacizumab is a phase 2 stage product being developed by Eli Lilly for Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00418093. Target conditions include Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00418093 | Phase 2 | Terminated |
| NCT00142467 | Phase 2 | Completed |
Competing Products
20 competing products in Ovarian Cancer